Compare CL & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CL | EW |
|---|---|---|
| Founded | 1806 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0B | 50.2B |
| IPO Year | 2007 | 1999 |
| Metric | CL | EW |
|---|---|---|
| Price | $88.07 | $84.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 21 |
| Target Price | $95.06 | ★ $96.47 |
| AVG Volume (30 Days) | ★ 5.2M | 4.6M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.63 | 1.83 |
| Revenue | ★ $15,454,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $7.62 | $13.39 |
| Revenue Next Year | $3.31 | $9.78 |
| P/E Ratio | ★ $34.06 | $46.57 |
| Revenue Growth | 1.70 | ★ 11.55 |
| 52 Week Low | $74.55 | $65.94 |
| 52 Week High | $99.33 | $87.89 |
| Indicator | CL | EW |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 55.46 |
| Support Level | $86.79 | $81.61 |
| Resistance Level | $88.55 | $87.22 |
| Average True Range (ATR) | 1.76 | 2.19 |
| MACD | -1.33 | 0.22 |
| Stochastic Oscillator | 0.48 | 69.95 |
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one-fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.